New York, October 06, 2016 -- Moody's Investors Service, ("Moody's") assigned a B1 rating to Concordia International Corp.'s ("Concordia") new senior secured notes. Moody's also affirmed the existing ratings of Concordia, including the B3 Corporate Family Rating and B3-PD Probability of Default Rating, the B1 on existing senior secured debt and the Caa2 on the senior unsecured notes. Moody's also affirmed the Speculative Grade Liquidity rating of SGL-2, signifying good liquidity. Moody's also changed the rating outlook to negative from stable.
Proceeds of the new senior secured notes will be used for general corporate purposes, including funding of pipeline products, small regional product acquisitions and upcoming contingent payments.
"While the notes offering improves liquidity over the next 12 months, it further increases Concordia's leverage at a time when the company is facing a number of business challenges" said Jessica Gladstone, Senior Vice President with Moody's. The change in outlook to negative reflects the risk that the company is not able to sustainably grow earnings given capital constraints and scrutiny on rising drug prices. The inability to grow earnings over the longer-term could lead to an unsustainable capital structure and challenges in refinancing. That said, liquidity remains good and the company has several years until it needs to address refinancing its debt.
The SGL-2 signifies our expectation for good liquidity over the next 12-18 months. The proceeds of the offering, together with operating cash flow, will provide sufficient liquidity to pay all acquisition related contingent payments and debt maturities over the next 12-18 months. Moody's anticipates there will also be sufficient liquidity to pursue modest size acquisitions that could be accretive to EBITDA. That said, the addition of a significant amount of secured debt to the capital structure substantially limits the company's use of the revolver because of the minimal cushion under the covenant, should it be tested. The covenant on the revolver is only tested if more than 30% is drawn.
Ratings affirmed:
Corporate Family Rating, B3
Probability of Default Rating, B3-PD
Senior Secured Rating, B1 (LGD2)
Senior Unsecured Rating, Caa2 (LGD5)
Speculative Grade Liquidity Rating, SGL-2
Ratings assigned:
$350 senior secured notes due 2022, B1 (LGD2)
Outlook to negative from stable.
RATINGS RATIONALE
The B3 Corporate Family Rating of Concordia reflects its very high financial leverage. Moody's estimates adjusted debt-to-EBITDA (following the contemplated notes offering) of nearly 8.0 times for the year ending December 31, 2016. The rating also reflects Moody's view that Concordia will be challenged to sustainably grow its revenue and earnings organically as many of its North America legacy products will decline. The company will either need to invest substantially to fill an internal R&D pipeline or will need to make acquisitions in order to sustain longer-term growth.
The rating is supported by the company's high profit margins, low cash taxes and low capital expenditures which will result in high conversion of revenue into free cash flow. The B3 is also supported by the company's good product and geographic diversity, as well as the expectation of good liquidity.
The ratings could be downgraded if Moody's expects leverage to increase from current levels or if liquidity weakens. Operating set-backs related to key products or material pricing pressure from regulatory changes or general drug pricing scrutiny that results in likely declines in earnings could lead to a downgrade.
The ratings could be upgraded if Concordia can demonstrate sustained organic revenue growth and stable cash generation. The ratings could be upgraded if Moody's expects debt to EBITDA to be sustained below 6.0x.
The principal methodology used in these ratings was Global Pharmaceutical Industry published in December 2012. Please see the Rating Methodologies page on www.moodys.com for a copy of this methodology.
Concordia is a pharmaceutical company focused on legacy products (i.e., those that have already substantially declined due to generic competition). Concordia is publicly listed on the Toronto Stock Exchange and on the NASDAQ with reported revenues of $745 million over the 12 months ended June 30, 2016.
REGULATORY DISCLOSURES
For ratings issued on a program, series or category/class of debt, this announcement provides certain regulatory disclosures in relation to each rating of a subsequently issued bond or note of the same series or category/class of debt or pursuant to a program for which the ratings are derived exclusively from existing ratings in accordance with Moody's rating practices. For ratings issued on a support provider, this announcement provides certain regulatory disclosures in relation to the credit rating action on the support provider and in relation to each particular credit rating action for securities that derive their credit ratings from the support provider's credit rating. For provisional ratings, this announcement provides certain regulatory disclosures in relation to the provisional rating assigned, and in relation to a definitive rating that may be assigned subsequent to the final issuance of the debt, in each case where the transaction structure and terms have not changed prior to the assignment of the definitive rating in a manner that would have affected the rating. For further information please see the ratings tab on the issuer/entity page for the respective issuer on www.moodys.com.
For any affected securities or rated entities receiving direct credit support from the primary entity(ies) of this credit rating action, and whose ratings may change as a result of this credit rating action, the associated regulatory disclosures will be those of the guarantor entity. Exceptions to this approach exist for the following disclosures, if applicable to jurisdiction: Ancillary Services, Disclosure to rated entity, Disclosure from rated entity.
Regulatory disclosures contained in this press release apply to the credit rating and, if applicable, the related rating outlook or rating review.
Please see www.moodys.com for any updates on changes to the lead rating analyst and to the Moody's legal entity that has issued the rating.
Please see the ratings tab on the issuer/entity page on www.moodys.com for additional regulatory disclosures for each credit rating.